Well, this thread can be shelved. FX-322 and FX-345 are both done.
Frequency Therapeutics Announces Topline Results for its Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss
"The Company will now discontinue the FX-322 development program. In addition, while dosing of...